Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Citrate/heparin/taurolidine - CorMedix Pharmaceuticals

X
Drug Profile

Citrate/heparin/taurolidine - CorMedix Pharmaceuticals

Alternative Names: Citrate/taurolidine/heparin; CRMD 003; CRMD 004; Defencath; Heparin/citrate/taurolidine; Heparin/taurolidine/citrate; Neutrolin; Taurolidine/citrate/heparin; Taurolidine/heparin/citrate

Latest Information Update: 03 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ND Partners
  • Developer CorMedix
  • Class Alkanesulfonic acids; Antibacterials; Anticoagulants; Antifungals; Citrates; Heparins; Small molecules; Thiadiazines
  • Mechanism of Action Cell adhesion molecule inhibitors; Deoxyribonuclease I stimulants; Factor Xa inhibitors; Heparanase inhibitors; Inflammation mediator inhibitors; Lipopolysaccharide inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Catheter infections

Most Recent Events

  • 27 Nov 2024 CorMedix initiates an expanded-access programme for Catheter infection (In prevention, In children, In adolescents, In adult, In the elderly) (NCT06707480)
  • 30 Oct 2024 CorMedix plans to initiated a clinical trial for Total Parenteral Nutrition (In adults) and anticipates commencing patient enrollment in the first half of 2025
  • 14 Aug 2024 CorMedix submits a complete clinical protocol to the FDA to gain further alignment for Total Parenteral Nutrition clinical trial

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top